Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation

Απλή σελίδα τεκμηρίου
dc.contributor.authorMinas, V.en
dc.contributor.authorRolaki, A.en
dc.contributor.authorKalantaridou, S. N.en
dc.contributor.authorSidiropoulos, J.en
dc.contributor.authorMitrou, S.en
dc.contributor.authorPetsas, G.en
dc.contributor.authorJeschke, U.en
dc.contributor.authorParaskevaidis, E. A.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorChrousos, G. P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorMakrigiannakis, A.en
dc.date.accessioned2015-11-24T19:09:10Z
dc.date.available2015-11-24T19:09:10Z
dc.identifier.issn0007-0920-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20663
dc.rightsDefault Licence-
dc.subjectApoptosis/immunologyen
dc.subjectBlotting, Westernen
dc.subjectCaspases/metabolismen
dc.subjectCell Line, Tumoren
dc.subjectCell Proliferationen
dc.subjectCorticotropin-Releasing Hormone/genetics/*metabolism/physiologyen
dc.subjectFas Ligand Protein/genetics/immunology/*metabolismen
dc.subjectFemaleen
dc.subjectFluorescent Antibody Technique, Indirecten
dc.subjectGene Expression Regulation, Neoplasticen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectLymphocytes/cytology/immunology/metabolismen
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/genetics/metabolism/*pathologyen
dc.subjectRNA, Messenger/genetics/metabolismen
dc.subjectReceptors, Corticotropin-Releasing Hormone/genetics/metabolismen
dc.subjectReverse Transcriptase Polymerase Chain Reactionen
dc.subjectUp-Regulationen
dc.titleIntratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulationen
heal.abstractAlthough corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established. FasL plays an important role in promoting tumour cells' ability to counterattack immune cells. Here, we examined immunohistochemically the expression of CRH, CRHR1, CRHR2 and FasL in 47 human ovarian cancer cases. The ovarian cancer cell lines OvCa3 and A2780 were further used to test the hypothesis that CRH might contribute to the immune privilege of ovarian tumours, by modulating FasL expression on the cancer cells. We found that CRH, CRHR1, CRHR2 and FasL were expressed in 68.1, 70.2, 63.8 and 63.8% of the cases respectively. Positivity for CRH or FasL expression was associated with higher tumour stage. Finally, CRH increased the expression of FasL in OvCa3 and A2780 cells through CRHR1 thereby potentiated their ability to induce apoptosis of activated peripheral blood lymphocytes. Corticotropin-releasing hormone produced by human ovarian cancer might favour survival and progression of the tumour by promoting its immune privilege. These findings support the hypothesis that CRHR1 antagonists could potentially be used against ovarian cancer.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1038/sj.bjc.6603918-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17667919-
heal.identifier.secondaryhttp://www.nature.com/bjc/journal/v97/n5/pdf/6603918a.pdf-
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
Minas-2007-Intratumoral CRH mod.pdf
Μέγεθος:
446.71 KB
Μορφότυπο:
Adobe Portable Document Format
Κατεβάστε

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ